Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,1 USD | +0,18% | +0,63% | -0,71% |
21/03 | Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024 | |
21/03 | Fennec Pharmaceuticals stijgt 3,2% in US Premarket, rapporteert een kleiner Q4-verlies van $0,10 per aandeel | MT |
Omzet 2023 | 21,25 mln. 19,72 mln. | Omzet 2024 * | 48,86 mln. 45,34 mln. | Marktkapitalisatie | 300 mln. 278 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -16 mln. -14,85 mln. | Nettowinst (verlies) 2024 * | 3 mln. 2,78 mln. | EV/omzet 2023 | 14,3 x |
Nettoliquiditeiten 2023 * | - 0 | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | 6,14 x |
K/w-verhouding 2023 |
-18,7
x | K/w-verhouding 2024 * |
88,7
x | Werknemers | 36 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 82,34% |
Recentste transcriptie over Fennec Pharmaceuticals Inc.
1 dag | +1,79% | ||
1 week | +0,14% | ||
Lopende maand | +17,05% | ||
1 maand | +18,56% | ||
3 maanden | -3,94% | ||
6 maanden | +54,82% | ||
Lopend jaar | -1,20% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 07-07-09 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 25-08-11 |
Khalid Islam
CHM | Chairman | 67 | 25-04-14 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 07-07-09 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 36 M€ | +4,74% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 11,14 | +0,50% | 79 399 |
27-03-24 | 11,08 | +1,79% | 102 037 |
26-03-24 | 10,89 | -1,00% | 122 955 |
25-03-24 | 11 | +1,85% | 206 484 |
22-03-24 | 10,8 | -2,44% | 175 183 |
uitgestelde koers Nasdaq, 27 maart 2024 om 21:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,20% | 300 mln. | |
+2,56% | 108 mld. | |
+10,02% | 104 mld. | |
+7,54% | 23,66 mld. | |
-11,91% | 22,1 mld. | |
-3,29% | 19,71 mld. | |
-35,98% | 18,2 mld. | |
-14,02% | 16,19 mld. | |
+4,61% | 13,72 mld. | |
+35,05% | 12,22 mld. |